The Office of the U.S. Trade Representative (USTR) has formally opened the regulatory docket for its Section 301 investigation into Germany’s pharmaceutical pricing practices, publishing a notice in the Federal Register that sets firm deadlines for public comments and schedules a hearing before the inter-agency Section 301 Committee. The notice, filed June 24, 2026, follows last week’s announcement that USTR had launched the investigation and provides the procedural roadmap importers, manufacturers, and trade associations will need to participate.
What the Federal Register Notice Adds
The Federal Register filing (Docket Nos. USTR-2026-0463 and USTR-2026-0464) confirms that the U.S. Trade Representative formally initiated the investigation on June 18, 2026, with the public comment docket opening June 25, 2026. The notice lays out a detailed procedural timeline:
- Written comments and hearing-appearance requests are due by 11:59 p.m. EDT on August 10, 2026.
- The Section 301 Committee will hold a public hearing on September 22, 2026, at the U.S. International Trade Commission in Washington, DC, continuing into a second day if necessary.
- Post-hearing rebuttal comments are due within seven calendar days of the hearing’s conclusion.
- All submissions, including business confidential information, must be filed through USTR’s online portal at comments.ustr.gov.
The Pricing Practices Under Scrutiny
Beyond procedure, the notice provides USTR’s most detailed public explanation yet of the specific German policies driving the case. USTR points to two mechanisms in particular. First, Germany conditions confidentiality of manufacturers’ pharmaceutical pricing on acceptance of a 9 percent price discount plus additional administrative costs. Second, draft legislation from Germany’s Ministry of Health would impose a new mandatory rebate on patented medicines starting in 2027, beginning at a fixed 3.5 percent rate before shifting to a variable formula tied to health-insurance fund expenditures — a rebate that, according to one estimate cited by USTR, could climb to 20 percent by 2030.
USTR frames the core economic harm in stark terms: U.S. consumers reportedly pay roughly 3.9 times more than German consumers for brand-name drugs, a gap the agency argues forces American patients to underwrite a disproportionate share of global pharmaceutical research and development costs. The investigation traces back to the May 2025 executive order on most-favored-nation drug pricing and a series of prior USTR comment requests on foreign pharmaceutical pricing practices dating to early 2025.
What This Means for Importers
With the docket now open, companies in the pharmaceutical, life sciences, and healthcare supply chains have a concrete window to act rather than simply monitor. Importers and trade associations with exposure to German-sourced pharmaceutical products or active ingredients should consider:
- Assessing supply chain exposure to German pharmaceutical manufacturers and intermediate goods now, ahead of any potential tariff determination.
- Preparing written comments by the August 10, 2026 deadline if the investigation’s outcome could affect sourcing, landed costs, or competitive positioning.
- Evaluating whether testimony at the September 22 hearing would be valuable, noting that requests to appear and summaries of testimony are also due August 10.
- Tracking that no tariffs have been proposed at this stage — the investigation must still proceed through a determination of actionability under Section 304 of the Trade Act before any responsive action, tariff or otherwise, can be taken.
Looking Ahead
This case adds to a growing list of active Section 301 proceedings and underscores USTR’s continued use of the statute as a primary enforcement tool against foreign pricing and trade practices. Importers should expect the pace of Section 301 activity to remain elevated through the second half of 2026, with the German pharmaceutical investigation serving as a test case for how aggressively USTR is willing to pursue pricing-related claims against a major U.S. trading partner.
ASK Alba™
Answers • Solutions • Knowledge
Need help assessing how the Section 301 Germany pharmaceutical investigation could affect your supply chain or sourcing strategy? Alba’s trade experts can help you evaluate exposure and prepare for potential outcomes.
Contact us at albawheelsup.com/contact-us/
Reference:
Office of the United States Trade Representative, Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany’s Persistent Underpayment for Innovative Pharmaceutical Products, 91 Fed. Reg. 38072 (June 24, 2026).
